PD-1 inhibitor promising in BCG-unresponsive NMIBC

Article

In this video interview with Urology Times, Arjun V. Balar, MD, PhD, discusses the current role of PD-1 inhibitors, their mechanism of action, and his own impression of recently presented phase II study data.

The PD-1 inhibitor pembrolizumab (KEYTRUDA) showed encouraging results in a phase II study of patients with high-risk, BCG-unresponsive nonmuscle-invasive bladder cancer with carcinoma in situ (CIS), researchers reported at the Society of Urologic Oncology annual meeting in Phoenix.

“What we have seen in this interim analysis, with a median follow-up of 14 months, is that the complete response rate in the bladder for patients with CIS, with or without papillary disease, is 38.8%,” said first author Arjun V. Balar, MD, PhD, of NYU Langone’s Perlmutter Cancer Center. “To see a 38.8% complete response rate, I think is quite promising, but we need longer term follow-up to determine how durable these responses are.”

In this video interview with Urology Times, Dr. Balar discusses the current role of PD-1 inhibitors, their mechanism of action, and his own impression of the current phase II study data.

 

Dr. Balar receives grants/research support from Genentech/Hoffman-La Roche, Merck, and Astra Zeneca; and is a consultant for Astra Zeneca/MedImmune, Genentech/Hoffman-La Roche, Merck, Pfizer, Incyte, and EMD Serono.

Related Videos
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Dr. David Braun in an interview with Urology Times
Dr. Neeraj Agarwal in an interview with Urology Times
Dr. Saby George in an interview with Urology Times
Dr. Laura Bukavina in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.